Calgary, Canada
Zenith Epigenetics Ltd., founded in 2013, is positioned at the forefront of biotech innovation with its focus on developing best-in-class bromodomain (BET) inhibitors to combat cancer and autoimmune diseases. By leveraging its cutting-edge epigenetic research, the company is targeting significant unmet medical needs in these areas.
Their flagship offering, a pan-selective BET inhibitor, is currently in clinical development targeting solid tumors like prostate cancer. This underscores their commitment to translating bromodomain biology into impactful therapies. Based in Canada, the company operates with a seasoned management and research team in Calgary and a translational medicine team in San Francisco, enabling seamless progression from discovery to clinical phases.
Part of the Zenith Capital Corp. family, the company's most recent financial milestone was a $4.00M venture round investment on 19 May 2015. Zenith's strategic focus and innovative approach firmly establish it in the biotechnology, healthcare, and pharmaceutical sectors.
